NASDAQ:CRNX - Crinetics Pharmaceuticals Stock Price, Forecast & News

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) issued its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by $0.03. The company earned $0.51 million during the quarter, compared to analysts' expectations of $0.33 million. View Crinetics Pharmaceuticals' Earnings History.

Crinetics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Crinetics Pharmaceuticals.

3 analysts have issued 1 year target prices for Crinetics Pharmaceuticals' shares. Their forecasts range from $35.00 to $40.00. On average, they expect Crinetics Pharmaceuticals' stock price to reach $37.33 in the next twelve months. This suggests a possible upside of 64.0% from the stock's current price. View Analyst Price Targets for Crinetics Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Crinetics Pharmaceuticals.

Media headlines about CRNX stock have been trending somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Crinetics Pharmaceuticals earned a coverage optimism score of 1.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 1,840,000 shares, a decrease of 9.8% from the December 15th total of 2,040,000 shares. Based on an average daily volume of 55,500 shares, the short-interest ratio is presently 33.2 days. Approximately 13.2% of the shares of the company are sold short. View Crinetics Pharmaceuticals' Current Options Chain.

Some companies that are related to Crinetics Pharmaceuticals include Ra Pharmaceuticals (RARX), Synthorx (THOR), Turning Point Therapeutics (TPTX), Prestige Consumer Healthcare (PBH), Aurinia Pharmaceuticals (AUPH), Xencor (XNCR), Aimmune Therapeutics (AIMT), Heron Therapeutics (HRTX), Eidos Therapeutics (EIDX), Cambrex (CBM), Principia Biopharma (PRNB), Ironwood Pharmaceuticals (IRWD), Zymeworks (ZYME), Insmed (INSM) and Pacira Biosciences (PCRX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include Agile Therapeutics (AGRX), Cidara Therapeutics (CDTX), Nektar Therapeutics (NKTR), Progenics Pharmaceuticals (PGNX), Athenex (ATNX), Aurinia Pharmaceuticals (AUPH), Concert Pharmaceuticals (CNCE), Corbus Pharmaceuticals (CRBP), CytomX Therapeutics (CTMX) and Fate Therapeutics (FATE).

(CRNX) raised $80 million in an initial public offering on Wednesday, July 18th 2018. The company issued 5,000,000 shares at $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CRNX stock can currently be purchased for approximately $22.76.

Crinetics Pharmaceuticals has a market capitalization of $551.25 million and generates $2.43 million in revenue each year. The company earns $-27,110,000.00 in net income (profit) each year or ($2.23) on an earnings per share basis. Crinetics Pharmaceuticals employs 47 workers across the globe.View Additional Information About Crinetics Pharmaceuticals.

The official website for Crinetics Pharmaceuticals is http://www.crinetics.com/.

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at 858-450-6464 or via email at [email protected]